Product Description
64Cu-SARTATE is being developed by Cleave Biosciences in patients with known or suspected neuroendocrine tumors and requiring a PET scan. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04438304?term=64Cu-SARTATE&draw=2&rank=1)
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cleave Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Neuroendocrine Tumors
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DISCO | P2 |
Active, not recruiting |
Neuroendocrine Tumors |
2024-10-01 |